Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 823.74% | 489.55% | 436.04% | 882.13% | -215.82% |
| Total Depreciation and Amortization | -14.69% | -27.54% | -37.31% | -43.26% | -34.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,907.42% | -972.59% | -1,193.31% | -290.97% | 141.24% |
| Change in Net Operating Assets | 488.44% | 583.88% | 87.63% | 96.85% | -187.92% |
| Cash from Operations | 67.60% | 18.31% | -8.71% | -33.73% | -962.57% |
| Capital Expenditure | 60.87% | 42.11% | 50.00% | -80.00% | 37.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 142.98% | -137.86% | -94.85% | -81.25% | -162.90% |
| Cash from Investing | 142.94% | -137.87% | -94.86% | -81.27% | -162.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -118.45% | -90.71% | -90.71% | -49.26% | -142,750.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -483.93% | 54.28% | 90.89% | 97.46% | -142,750.00% |
| Foreign Exchange rate Adjustments | -512.50% | -75.00% | -650.00% | 583.33% | 242.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.20% | -209.61% | -118.68% | -72.50% | -188.42% |